Eli Lilly’s Alzheimer’s drug, Kisunla, has received approval from the Japanese Ministry of Health, Labour and Welfare. This ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

(RTTNews) - Eli Lilly and Company (LLY) Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare ...

Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), ...

Eli Lilly on Tuesday said Japan's Ministry of Health, Labour and Welfare Japan approved Kisunla for adults with early symptomatic Alzheimer's, including those with mild cognitive impairment as well as ...

Lilly said Japan is the second major market in which the drug has received approval, after the United States where it is sold ...

Two new drug treatments prove effective in forestalling the start of early onset Alzheimer's; Roskamp will eventually offer ...

Storm Track 8 meteorologist Tara Hastings is one of millions of people around the world who cares for a loved one with Alzheimer's.

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

Because the question with Kisunla, there will be -- this market is plenty big for ... The tide doesn't rise immediately. It's not like Lilly comes in and suddenly there's 9,000 new neurologists that ...